秋水仙碱抗动脉粥样硬化炎症的机制及临床突破  

Mechanism and clinical breakthrough of colchicine against atherosclerotic inflammation

作　　者：李楠楠 莫显刚 LI Nannan;MO Xiangang(Guizhou Medical University,Guizhou,Guiyang 550004,China)

机构地区：[1]贵州医科大学,贵阳市550004 [2]贵州医科大学附属医院综合病房

出　　处：《河北医药》2025年第3期472-477,共6页Hebei Medical Journal

基　　金：国家自然科学基金(编号:82160097)。

摘　　要：动脉粥样硬化(Atherosclerosis,AS)是一种复杂的炎症过程。AS可通过生活方式的调整、药物及手术治疗进行管理和控制。但现研究更着重于通过靶向炎症途径从而有效控制AS性疾病在常规治疗下所不能解决的残余炎症现象。本研究总结了秋水仙碱(Colchicine)由于其独特的抗炎机制,能够干预参与AS斑块形成的细胞过程,结合近年来的大量实验研究结果,发现其成为AS二级预防的重要候选药物。新兴的靶向纳米递送平台技术能最大限度地减少Colchicine所带来的不良反应,如消化道症状、肝脏损害、感染等。但未来仍需要进行研究来完善其临床应用,特别是与先进的给药途径相结合的新疗法。本文就Colchicine的抗炎机制及其在AS进展中的临床潜力作一综述。Atherosclerosis(AS)is a complex inflammatory process.AS can be managed and controlled by lifestyle modification,medication and surgical treatment.However,current studies have focused more on targeting inflammatory pathways to effectively control the residual inflammation that cannot be solved by conventional treatment of AS.This study summarized the role of colchicine,due to its unique anti-inflammatory mechanism,in intervening in the cellular processes involved in the formation of atherosclerotic plaques.Combined with the findings from massive experimental studies in recent years,colchicine has become an important candidate drug for the secondary prevention of AS.The emerging targeted nano-delivery platform technology can minimize the adverse effects caused by colchicine,such as gastrointestinal symptoms,liver damage,and infection.However,future studies are needed to perfect its clinical application,especially for new therapies combined with advanced routes of administration.This article reviewed the anti-inflammatory mechanism of colchicine and its clinical potential in the progression of AS.

关 键 词：秋水仙碱 动脉粥样硬化 炎症 心血管疾病 

分 类 号：R543.5[医药卫生—心血管疾病]